Improved RP-HPLC method to determine biapenem in human plasma/urine and its application to a pharmacokinetic study

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 3, 2011, Pages 197-204

  Zhao, Libo ^a   Liu, Yi ^a   Kou, Zhibin ^a   Bayasi, Aidijie ^a   Cai, Huan ^a   Zhang, Chunyan ^a   Wang, Qian ^a   Li, Yuzhen ^a   Fang, Yi ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antibacterial; Biapenem; CAS 120410 24 4; Human plasma and urine; Pharmacokinetics; RP HPLC

Indexed keywords

ACETIC ACID; ACETONITRILE; BIAPENEM; CAS 120410 24 4; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; STANDARD; ULTRAFILTRATION;

EID: 79953251259     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296189     Document Type: Article

References (29)

1. Bonfiglio G, Maccarone G, Mezzatesta ML, Privitera A, Carciotto V, Santagati M, et al. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates. Chemotherapy. 1997;43:393-9.
2. Malanoski GJ, Collins L, Wennersten C, Moellering RC, Eliopoulos GM. In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 1993;37:2009-16.
3. Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, et al. In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998. Jpn J Antibiot. 1999;52:690-4.
4. Hikida M, Kawashima K, Nishiki K, Furukawa Y, Nishizawa K, Saito I, et al. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother. 1992;36:481-3.
5. Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother. 1990;34:994-1000.
6. Watanabe A, Kikuchi H, Kikuchi T, Lutfor AB, Tokue Y, Takahashi H, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother. 1999;5:171-5. (Pubitemid 29484865)
7. Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, et al., Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother. 2001;7:267-71.
8. Nakashima M, Uematsu T, Ueno K, Nagashima S, Inaba H, Nakano M, et al. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Clin Pharmacol Ther Toxicol. 1993;31:70-6. (Pubitemid 23088087)
9. Kusumoto Y, Akita H, Sato Y, Iwata S, Takeuchi Y, Abe T, et al. Bacteriological and clinical studies of biapenem (L-627) in pediatrics. Jpn J Antibiot. 1994;47:921-31. (Pubitemid 24246586)
10. Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother. 1998;42: 1433-6. (Pubitemid 28257646)
11. Nagashima S, Kozawa O, Otsuka T, Kohno K, Minamoto M, Yokokawa M, et al. Pharmacokinetics of a parenteral carba- penem, biapenem, in patients with end-stage renal disease and influence of haemodialysis. J Antimicrob Chemother. 2000;46:839-42.
12. Deng L, Huang W. Pharmacokinetics of a parenteral carbapenem antibiotic, biapenem, in Chinese healthy volunteers. Chin J Antibiot. 2008;33:717-20.
13. Hu Y, Yang H, He Y, Zhang Y. Pharmacokinetcs and serum concentration of biapenem in healthy volunteers. Chin J New Drugs Clin Rem. 2008;27:500-3.
14. Wu X, Yu. J, Zhang J, Cao G, Shi Y, Zhang Y. Determination of biapenem in human plasma and urine by a simple HPLC method for its pharmacokinetics study. J Chin PharmSci. 2009;18:177-82.
15. Jin X, Pan J, Han J, Lei X, Meng L. Pharmacokinetics of single and multiple oral doses of biapenem in healthy volunteers. Chin Hosp PharmJ. 2009;29:817-20.
16. Ikeda K, Ikawa K, Ikeda A, Nishikawa Y, Morikawa N. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;844:148-52. (Pubitemid 46048603)
17. Ikawa K, Morikawa N, Ikeda K, Suyama H. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration. J Infect Chemother. 2008;14:35-9. (Pubitemid 351311438)
18. Motohiro T, Handa S, Yamada S, Oki S, Yoshinaga Y, Oda K, et al. Bacteriological, pharmacokinetic and clinical studies on biapenem (L-627) in the pediatric field. Jpn J Antibiot. 1994;47:1728-52.
19. Suyama H, Ikawa K, Morikawa N, Ikeda K, Fujiue Y, Morikawa S, et al. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Jpn J Antibiot. 2008;61:303-13.
20. Kikuchi E, Kikuchi J, Nasuhara Y, Oizumi S, Ishizaka A, Nishimura M. Comparison of the pharmacodynamics of biapenem in bronchial epithelial lining fluid in healthy volunteers given half-hour and three-hour intravenous infusions. Antimicrob Agents Chemother. 2009;53:2799-803.
21. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T, Suyama H, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy. Chemotherapy. 2008;54:386-94.
22. Kameda K, Miki M, Ikawa K, Morikawa N, Kobayashi M. Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation. Jpn J Antibiot. 2009;62:1-8.
23. Nagasawa Z, Kusaba K, Aoki Y. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation. J Infect Chemother. 2008;14:238-43. (Pubitemid 351875923)
24. Nakamura T, Shimizu C, Kasahara M, Okuda K, Nakata C, Fujimoto H, et al. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli. J Infect Chemother. 2009; 15:13-7.
25. Niwa T, Nakamura A, Kato T, Kutsuna T, Katou K, Morita H, et al. Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006;100:324-31. (Pubitemid 43078986)
26. Kurihara Y, Kizu J, Hori S. Simple and rapid determination of serum carbapenem concentrations by high-performance liquid chromatography. J Infect Chemother. 2008;14: 30-4. (Pubitemid 351311442)
27. Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl. 1997;692:127-32. (Pubitemid 27208473)
28. Musson DG, Majumdar A, Birk K, Holland S,WickershamP, Li SX, et al. Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother. 2003;47: 1732-5. (Pubitemid 36548562)
29. Gordien JB, Boselli E, Fleureau C, Allaouchiche B, Janvier G, Lalaude O, et al. Determination of free ertapenem in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:218-23. (Pubitemid 43075454)